Pub Date : 2025-10-01Epub Date: 2025-08-21DOI: 10.1016/j.leukres.2025.108087
Siri Ravipati , Waffa Bakheet , Indryas Woldie , Rasna Gupta , Greg Yousif , Hadeja Faraj , Abdulkadir Hussein , Rong Luo , Andrea Cervi , Gopila Gupta , Sindu Kanjeekal , Sahar Khan , Caroline Hamm
Treatment Free Remission (TFR) is an established goal for patients with the diagnosis of chronic myeloid leukemia (CML). The purpose of this prospective feasibility pilot study was assessing a new, real-world paradigm for safely stopping TKI treatment by monitoring molecular response through PCR tests determining BCR::ABL levels every 6 weeks instead of the recommended 4-week intervals. A successful re-establishment of MMR after loss of TFR was the primary endpoint. Eligibility criteria for this study included maintaining major molecular response 4 log reduction (MMR4) for 2 years and a total of TKI therapy for 5 years. The primary endpoint was successful maintenance of ≥ MMR at 6 months. 18 patients were enrolled, 13 of the 18 participants maintained TFR, and all 5 patients regained MMR with resumption of TKI treatment. We demonstrated that this pilot study was feasible in a community setting using 6-week intervals. This study will be expanded to other sites using a 6-week testing interval.
{"title":"Pilot study: A prospective, real-world, feasibility study testing a decreased frequency paradigm in treatment free remission in chronic myeloid leukemia","authors":"Siri Ravipati , Waffa Bakheet , Indryas Woldie , Rasna Gupta , Greg Yousif , Hadeja Faraj , Abdulkadir Hussein , Rong Luo , Andrea Cervi , Gopila Gupta , Sindu Kanjeekal , Sahar Khan , Caroline Hamm","doi":"10.1016/j.leukres.2025.108087","DOIUrl":"10.1016/j.leukres.2025.108087","url":null,"abstract":"<div><div>Treatment Free Remission (TFR) is an established goal for patients with the diagnosis of chronic myeloid leukemia (CML). The purpose of this prospective feasibility pilot study was assessing a new, real-world paradigm for safely stopping TKI treatment by monitoring molecular response through PCR tests determining BCR::ABL levels every 6 weeks instead of the recommended 4-week intervals. A successful re-establishment of MMR after loss of TFR was the primary endpoint. Eligibility criteria for this study included maintaining major molecular response 4 log reduction (MMR4) for 2 years and a total of TKI therapy for 5 years. The primary endpoint was successful maintenance of ≥ MMR at 6 months. 18 patients were enrolled, 13 of the 18 participants maintained TFR, and all 5 patients regained MMR with resumption of TKI treatment. We demonstrated that this pilot study was feasible in a community setting using 6-week intervals. This study will be expanded to other sites using a 6-week testing interval.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"157 ","pages":"Article 108087"},"PeriodicalIF":2.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144890698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01Epub Date: 2025-09-05DOI: 10.1016/j.leukres.2025.108089
Ehab L. Atallah , Islam Sadek , David Wei , Dominick Latremouille-Viau , Carmine Rossi , Andrea Damon , Daisy Yang , Remi Bellefleur , Annie Guérin , Kejal Jadhav
Background
In chronic-phase chronic myeloid leukemia (CML-CP), switching tyrosine kinase inhibitor (TKI) therapy due to intolerance or resistance is common. While asciminib, an ABL/BCR::ABL1 TKI targeting the ABL myristoyl pocket, offers improved tolerability and efficacy, there is limited real-world effectiveness data, particularly among patients with treatment with one prior TKI.
Patients and methods
A retrospective, US physician panel-based chart review study was conducted on adult patients with CML-CP without T315I treated with asciminib after one prior TKI. Time-on-treatment, and time-to achieving or maintaining MR2 (BCR::ABL1 ≤ 1 %), MMR (BCR::ABL1 ≤ 0.1 %) and DMR (BCR::ABL1 ≤ 0.01 %) were assessed using Kaplan-Meier analyses. Subgroup analyses were performed among patients with first TKI discontinuation due to intolerance or resistance, and by first- or second-generation TKI as first TKI.
Results
Overall, 255 patients (median age 62 years, 56.5 % male) were included. Imatinib (49.8 %), dasatinib (34.5 %), nilotinib (10.6 %), and bosutinib (5.1 %) were received as first TKI. Intolerance and resistance to first TKIs were reported for 43.5 % and 23.5 % of patients, respectively. At 48-weeks post-asciminib initiation, 95.0 % of patients (95 % CI: 91.3 %, 97.1 %) remained on asciminib, 84.0 % (95 % CI: 78.6 %, 88.6 %) achieved or maintained MR2, 68.3 % (95 % CI: 61.8 %, 74.5 %) MMR, and 40.6 % (95 % CI: 34.2 %, 47.8 %) DMR.
Conclusions
Overall, most patients remained on treatment and achieved or maintained MMR, suggesting that asciminib was well-tolerated and effective. Results were consistent among subgroups, indicating that asciminib is an effective option for patients regardless of prior TKI used, and including those intolerant or resistant to their first TKI.
Micro-abstract
There is limited real-world data regarding the effectiveness of asciminib after one prior tyrosine kinase inhibitor (TKI) in chronic-phase chronic myeloid leukemia (CML-CP). In this US physician panel-based chart review, nearly all patients (95 %) remained on asciminib and 68 % achieved or maintained a major molecular response at 48 weeks, suggesting that asciminib is well-tolerated and effective after one prior TKI.
{"title":"Treatment with asciminib after a prior tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia","authors":"Ehab L. Atallah , Islam Sadek , David Wei , Dominick Latremouille-Viau , Carmine Rossi , Andrea Damon , Daisy Yang , Remi Bellefleur , Annie Guérin , Kejal Jadhav","doi":"10.1016/j.leukres.2025.108089","DOIUrl":"10.1016/j.leukres.2025.108089","url":null,"abstract":"<div><h3>Background</h3><div>In chronic-phase chronic myeloid leukemia (CML-CP), switching tyrosine kinase inhibitor (TKI) therapy due to intolerance or resistance is common. While asciminib, an ABL/BCR::ABL1 TKI targeting the ABL myristoyl pocket, offers improved tolerability and efficacy, there is limited real-world effectiveness data, particularly among patients with treatment with one prior TKI.</div></div><div><h3>Patients and methods</h3><div>A retrospective, US physician panel-based chart review study was conducted on adult patients with CML-CP without T315I treated with asciminib after one prior TKI. Time-on-treatment, and time-to achieving or maintaining MR2 (BCR::ABL1 ≤ 1 %), MMR (BCR::ABL1 ≤ 0.1 %) and DMR (BCR::ABL1 ≤ 0.01 %) were assessed using Kaplan-Meier analyses. Subgroup analyses were performed among patients with first TKI discontinuation due to intolerance or resistance, and by first- or second-generation TKI as first TKI.</div></div><div><h3>Results</h3><div>Overall, 255 patients (median age 62 years, 56.5 % male) were included. Imatinib (49.8 %), dasatinib (34.5 %), nilotinib (10.6 %), and bosutinib (5.1 %) were received as first TKI. Intolerance and resistance to first TKIs were reported for 43.5 % and 23.5 % of patients, respectively. At 48-weeks post-asciminib initiation, 95.0 % of patients (95 % CI: 91.3 %, 97.1 %) remained on asciminib, 84.0 % (95 % CI: 78.6 %, 88.6 %) achieved or maintained MR2, 68.3 % (95 % CI: 61.8 %, 74.5 %) MMR, and 40.6 % (95 % CI: 34.2 %, 47.8 %) DMR.</div></div><div><h3>Conclusions</h3><div>Overall, most patients remained on treatment and achieved or maintained MMR, suggesting that asciminib was well-tolerated and effective. Results were consistent among subgroups, indicating that asciminib is an effective option for patients regardless of prior TKI used, and including those intolerant or resistant to their first TKI.</div></div><div><h3>Micro-abstract</h3><div>There is limited real-world data regarding the effectiveness of asciminib after one prior tyrosine kinase inhibitor (TKI) in chronic-phase chronic myeloid leukemia (CML-CP). In this US physician panel-based chart review, nearly all patients (95 %) remained on asciminib and 68 % achieved or maintained a major molecular response at 48 weeks, suggesting that asciminib is well-tolerated and effective after one prior TKI.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"157 ","pages":"Article 108089"},"PeriodicalIF":2.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145054377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01Epub Date: 2025-07-15DOI: 10.1016/j.leukres.2025.107919
Andreas Reiter , Jason Gotlib , Iván Álvarez-Twose , Deepti H. Radia , Johannes Lübke , Priyanka J. Bobbili , Aolin Wang , Saša Dimitrijević , Erin Sullivan , Juliana Schwaab , Ilene A. Galinsky , Cecelia Perkins , Wolfgang R. Sperr , Priya Sriskandarajah , Manasi Mohan , Teshawna Badu , Selvam R. Sendhil , Mei Sheng Duh , Peter Valent , Daniel J. DeAngelo
As there are no prospective randomized studies in patients with advanced systemic mastocytosis (AdvSM), we compared clinical outcomes between patients treated with avapritinib in the Phase I EXPLORER (NCT02561988) and Phase II PATHFINDER (NCT03580655) trials (N = 176) and patients treated with midostaurin (N = 99) or cladribine (N = 49) from a global, multi-center, retrospective, chart review study. Overall survival (OS) and duration of treatment (DOT) were compared between the cohorts using inverse probability of treatment weighting (IPTW)-adjusted Cox proportional hazards models, and maximum reduction in serum tryptase levels was compared using adjusted generalized linear models. Median OS was not reached (95% confidence interval [CI]: 46.9 months, not estimable) for avapritinib, 28.6 (18.2, 44.6) months for midostaurin, and 23.4 (14.8, 40.6) months for cladribine. The avapritinib cohort had significantly longer OS compared to midostaurin (hazard ratio [HR] [95% CI]: 0.59 [0.36, 0.97]) and cladribine (0.32 [0.15, 0.67]), longer DOT (vs. midostaurin: 0.63 [0.41, 0.96]; vs. cladribine: 0.14 [0.09, 0.23]), and greater reduction in serum tryptase levels with mean difference [95% CI] vs. midostaurin of −72.8 % [−101.1 %, −44.6 %] and vs. cladribine of −25.0 % [−32.4 %, −17.7 %] (all p < 0.05). Results were similar in treatment-naïve (1 L) and previously treated (2 L+) patients; there was improved OS in 1 L avapritinib vs. 1 L midostaurin patients (HR: 0.14 [0.05, 0.42]; p < 0.001) and in 2 L+ avapritinib vs. 2 L+ cladribine patients (0.34 [0.16, 0.71]; p = 0.004). Together, we show that avapritinib treatment resulted in significantly improved OS, longer DOT, and greater reduction in serum tryptase levels compared to midostaurin or cladribine in real-world clinical practice.
{"title":"Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control study","authors":"Andreas Reiter , Jason Gotlib , Iván Álvarez-Twose , Deepti H. Radia , Johannes Lübke , Priyanka J. Bobbili , Aolin Wang , Saša Dimitrijević , Erin Sullivan , Juliana Schwaab , Ilene A. Galinsky , Cecelia Perkins , Wolfgang R. Sperr , Priya Sriskandarajah , Manasi Mohan , Teshawna Badu , Selvam R. Sendhil , Mei Sheng Duh , Peter Valent , Daniel J. DeAngelo","doi":"10.1016/j.leukres.2025.107919","DOIUrl":"10.1016/j.leukres.2025.107919","url":null,"abstract":"<div><div>As there are no prospective randomized studies in patients with advanced systemic mastocytosis (AdvSM), we compared clinical outcomes between patients treated with avapritinib in the Phase I EXPLORER (NCT02561988) and Phase II PATHFINDER (NCT03580655) trials (N = 176) and patients treated with midostaurin (N = 99) or cladribine (N = 49) from a global, multi-center, retrospective, chart review study. Overall survival (OS) and duration of treatment (DOT) were compared between the cohorts using inverse probability of treatment weighting (IPTW)-adjusted Cox proportional hazards models, and maximum reduction in serum tryptase levels was compared using adjusted generalized linear models. Median OS was not reached (95% confidence interval [CI]: 46.9 months, not estimable) for avapritinib, 28.6 (18.2, 44.6) months for midostaurin, and 23.4 (14.8, 40.6) months for cladribine. The avapritinib cohort had significantly longer OS compared to midostaurin (hazard ratio [HR] [95% CI]: 0.59 [0.36, 0.97]) and cladribine (0.32 [0.15, 0.67]), longer DOT (vs. midostaurin: 0.63 [0.41, 0.96]; vs. cladribine: 0.14 [0.09, 0.23]), and greater reduction in serum tryptase levels with mean difference [95% CI] vs. midostaurin of −72.8 % [−101.1 %, −44.6 %] and vs. cladribine of −25.0 % [−32.4 %, −17.7 %] (all <em>p</em> < 0.05). Results were similar in treatment-naïve (1 L) and previously treated (2 L+) patients; there was improved OS in 1 L avapritinib vs. 1 L midostaurin patients (HR: 0.14 [0.05, 0.42]; <em>p</em> < 0.001) and in 2 L+ avapritinib vs. 2 L+ cladribine patients (0.34 [0.16, 0.71]; <em>p</em> = 0.004). Together, we show that avapritinib treatment resulted in significantly improved OS, longer DOT, and greater reduction in serum tryptase levels compared to midostaurin or cladribine in real-world clinical practice.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"157 ","pages":"Article 107919"},"PeriodicalIF":2.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144704856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Myelodysplastic syndrome (MDS) is a hematological malignancy characterized by the clonal expansion of mutated hematopoietic stem and progenitor cells, resulting in morphological changes (dysplasia) in the bone marrow and cytopenia. Despite advancements in molecular diagnostics, MDS diagnosis often depends on subjective morphological evaluation of bone marrow smears. One objective criterion is cytogenetic analysis. Here, we present a deep learning-based approach to identify morphological abnormalities associated with cytogenetically defined MDS (cMDS) using whole slide images (WSIs) of bone marrow smears. To disentangle shape and textural features in WSIs, we developed a model analyzing segmented binary masks of red blood cells (RBCs) in addition to a conventional image classification model based on color images. Notably, the RBC morphology model achieved high diagnostic accuracy, even after controlling for anemia, uncovering a strong association between RBC shape and distribution—features previously overlooked by human experts—and cMDS. These findings propose RBC morphology as a novel biomarker for MDS and underscore the potential of artificial intelligence to enhance diagnostic precision and objectivity.
{"title":"Deep learning-based morphological assessment of myelodysplastic syndrome on bone marrow smears","authors":"Shizuo Kaji , Hiroki Kawai , Kei Shimbo , Tomoya Maeda , Akira Matsuda , Jinichi Mori","doi":"10.1016/j.leukres.2025.107923","DOIUrl":"10.1016/j.leukres.2025.107923","url":null,"abstract":"<div><div>Myelodysplastic syndrome (MDS) is a hematological malignancy characterized by the clonal expansion of mutated hematopoietic stem and progenitor cells, resulting in morphological changes (dysplasia) in the bone marrow and cytopenia. Despite advancements in molecular diagnostics, MDS diagnosis often depends on subjective morphological evaluation of bone marrow smears. One objective criterion is cytogenetic analysis. Here, we present a deep learning-based approach to identify morphological abnormalities associated with cytogenetically defined MDS (cMDS) using whole slide images (WSIs) of bone marrow smears. To disentangle shape and textural features in WSIs, we developed a model analyzing segmented binary masks of red blood cells (RBCs) in addition to a conventional image classification model based on color images. Notably, the RBC morphology model achieved high diagnostic accuracy, even after controlling for anemia, uncovering a strong association between RBC shape and distribution—features previously overlooked by human experts—and cMDS. These findings propose RBC morphology as a novel biomarker for MDS and underscore the potential of artificial intelligence to enhance diagnostic precision and objectivity.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"157 ","pages":"Article 107923"},"PeriodicalIF":2.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144749661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01Epub Date: 2025-08-07DOI: 10.1016/j.leukres.2025.107925
Amir T. Fathi, B. Douglas Smith, Anne Angiolillo, Gary Binder, Assaf Vestin, Jianan Hui, Rachel Guo, Claudio Cerchione
{"title":"Time to recovery from neutropenia in patients with newly diagnosed IDH-1 mutated acute myeloid leukemia receiving azacitidine and ivosidenib in the AGILE clinical trial","authors":"Amir T. Fathi, B. Douglas Smith, Anne Angiolillo, Gary Binder, Assaf Vestin, Jianan Hui, Rachel Guo, Claudio Cerchione","doi":"10.1016/j.leukres.2025.107925","DOIUrl":"10.1016/j.leukres.2025.107925","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"157 ","pages":"Article 107925"},"PeriodicalIF":2.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144865930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In a rare condition known as AIHA (Autoimmune Hemolytic Anemia), red blood cells are destroyed by the immune system. This type of anemia is it. More creative therapeutic options have emerged as a result of AIHA therapy outcomes, and these are thought to significantly improve the patient's condition. This summary sheds light on novel therapies that target specific pathways. B-cell-directed therapies, phagocytosis inhibitors, complement inhibitors, and FcRn inhibitors are examples of patient-specific, pathway-oriented treatments. These innovative treatments, which are yet to be implemented in clinical settings, have the potential to enhance the management of AIHA and can be used in conjunction with other treatments that have fewer side effects than conventional therapies. In addition to their potential, methods in this emerging field also make clinical adoption challenging. Striking a balance between delivering cutting-edge care and protecting physicians' income is difficult due to the high costs. Because they maximize treatment outcomes and enable treatments to be precisely tailored to each patient's unique needs, individualized medicine and combined therapies are extremely advantageous. To fully realize the potential of AIHA therapies and transform the way AIHA is managed, a number of obstacles must be removed and these treatments made easily accessible to all.
{"title":"Advancements in Autoimmune Hemolytic Anemia (AIHA) treatment: Exploring emerging therapies","authors":"Debanjan Mukherjee , Prabhjot Kaur , Amandeep Singh , Manish Kumar , Sheeba Shafi , Prabhat Kumar Upadhyay , Abhishek Tiwari , Varsha Tiwari , Naresh Kumar Rangra , Vidhya Thirunavukkarasu , Sheeba Kumari , Nidhi Arora , Yukta Garg , Nandini Sharma","doi":"10.1016/j.leukres.2025.107910","DOIUrl":"10.1016/j.leukres.2025.107910","url":null,"abstract":"<div><div>In a rare condition known as AIHA (Autoimmune Hemolytic Anemia), red blood cells are destroyed by the immune system. This type of anemia is it. More creative therapeutic options have emerged as a result of AIHA therapy outcomes, and these are thought to significantly improve the patient's condition. This summary sheds light on novel therapies that target specific pathways. B-cell-directed therapies, phagocytosis inhibitors, complement inhibitors, and FcRn inhibitors are examples of patient-specific, pathway-oriented treatments. These innovative treatments, which are yet to be implemented in clinical settings, have the potential to enhance the management of AIHA and can be used in conjunction with other treatments that have fewer side effects than conventional therapies. In addition to their potential, methods in this emerging field also make clinical adoption challenging. Striking a balance between delivering cutting-edge care and protecting physicians' income is difficult due to the high costs. Because they maximize treatment outcomes and enable treatments to be precisely tailored to each patient's unique needs, individualized medicine and combined therapies are extremely advantageous. To fully realize the potential of AIHA therapies and transform the way AIHA is managed, a number of obstacles must be removed and these treatments made easily accessible to all.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"156 ","pages":"Article 107910"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144623448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01Epub Date: 2025-09-10DOI: 10.1016/j.leukres.2025.107805
Linlin Liu , Bing Li , Tiejun Qin , Zefeng Xu , Shiqiang Qu , Lijuan Pan , Qingyan Gao , Meng Jiao , Yujiao Jia , Chengwen Li , Qi Sun , Huijun Wang , Zhijian Xiao , Xin Wang
{"title":"RAPID FIRE SESSION 02","authors":"Linlin Liu , Bing Li , Tiejun Qin , Zefeng Xu , Shiqiang Qu , Lijuan Pan , Qingyan Gao , Meng Jiao , Yujiao Jia , Chengwen Li , Qi Sun , Huijun Wang , Zhijian Xiao , Xin Wang","doi":"10.1016/j.leukres.2025.107805","DOIUrl":"10.1016/j.leukres.2025.107805","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"156 ","pages":"Article 107805"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145060507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01Epub Date: 2025-09-10DOI: 10.1016/j.leukres.2025.107781
Willemijn Hobo , Diede Van Ens , Saskia Langemeijer , Jolanda Brummelman , Carolien Duetz , Mylene Gerritsen , Luca Janssen , Jesper Van Eck Van Der Sluijs , Rob Woestenenk , Daan Heister , Theresia Scheele , Wim Rijnen , Suzanne Van Dorp , Mieke Roeven , Joop Jansen , Anniek Van Der Waart , Marisa Westers , Arjan Van De Loosdrecht , Harry Dolstra
{"title":"PLENARY SESSION 2: IMMUNOLOGY AND MICROENVIRONMENT IN MDS","authors":"Willemijn Hobo , Diede Van Ens , Saskia Langemeijer , Jolanda Brummelman , Carolien Duetz , Mylene Gerritsen , Luca Janssen , Jesper Van Eck Van Der Sluijs , Rob Woestenenk , Daan Heister , Theresia Scheele , Wim Rijnen , Suzanne Van Dorp , Mieke Roeven , Joop Jansen , Anniek Van Der Waart , Marisa Westers , Arjan Van De Loosdrecht , Harry Dolstra","doi":"10.1016/j.leukres.2025.107781","DOIUrl":"10.1016/j.leukres.2025.107781","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"156 ","pages":"Article 107781"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145060627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01Epub Date: 2025-09-10DOI: 10.1016/j.leukres.2025.107811
Araceli Sama Barroso , Andrés Durán Adame , Ignacio García-Tuñón Llanio , Maria Gabarros , Irene Rodriguez Iglesias , Bárbara Frades Pérez , Ana María Sánchez Cuesta , María Victoria Cascajo Almenara , Carlos Santos Ocaña , Ana Alfonso-Pierola , Laura Palomo Sanchís , Adrián Mosquera Orgueira , Jesús Hernández Rivas , Maria Diez-Campelo , Andres Jerez , Mónica Del Rey
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号